HER2-positive breast cancer frequently metastasizes to the lungs [7, 8], but preclinical models for multiresistant lung metastases are lacking, which hampers the development of novel therapeutic agents and strategies for such patients. This evidence concerns the gene ERBB2 and breast carcinoma.